Recursion Pharmaceuticals, Inc.
RXRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$463,661 | -$328,066 | -$239,476 | -$186,479 |
| Dep. & Amort. | $36,494 | $24,402 | $11,756 | $8,405 |
| Deferred Tax | $0 | $0 | $0 | $827 |
| Stock-Based Comp. | $81,688 | $53,503 | $27,909 | $14,842 |
| Change in WC | -$38,001 | -$50,257 | $104,921 | -$306 |
| Other Non-Cash | $24,306 | $12,638 | $11,366 | $4,097 |
| Operating Cash Flow | -$359,174 | -$287,780 | -$83,524 | -$158,614 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$13,695 | -$11,955 | -$37,059 | -$39,798 |
| Net Acquisitions | $277,104 | $1,844 | $0 | $231,946 |
| Inv. Purchases | $0 | $0 | $0 | -$301,137 |
| Inv. Sales/Matur. | $0 | $480 | $230,608 | $69,191 |
| Other Inv. Act. | -$3,350 | -$597 | -$300 | -$231,946 |
| Investing Cash Flow | $260,059 | -$10,228 | $193,249 | -$271,744 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$4,440 | -$766 | -$90 | -$12,798 |
| Stock Issued | $300,417 | $128,093 | $143,711 | $462,901 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $8,143 | $12,806 | $10,724 | $8,437 |
| Financing Cash Flow | $304,120 | $140,133 | $154,345 | $458,540 |
| Forex Effect | -$3,406 | $188 | -$307 | $0 |
| Net Chg. in Cash | $201,599 | -$157,687 | $263,763 | $28,182 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $401,425 | $559,112 | $295,349 | $267,167 |
| End Cash | $603,024 | $401,425 | $559,112 | $295,349 |
| Free Cash Flow | -$372,869 | -$300,332 | -$120,883 | -$198,412 |